The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Performance of manufactured batteries has improved over time. For example, from 1991 to 2005 the energy capacity per price of lithium-ion batteries improved more than ten-fold, from 0.3 W·h per dollar to over 3 W·h per dollar. In the period from 2011 to 2017, progress has averaged 7.5% annually. Overall, between 1991 and 2024, prices for all types of lithium-ion cells (in dollars per kWh) fell approximately 99%. From 1991 to 2018, energy density more than tripled. Efforts to increase energy density contributed significantly to cost reduction. Energy density can also be increased by improvements in the chemistry of the cell, for instance, by full or partial replacement of graphite with silicon. Silicon anodes enhanced with graphene nanotubes to eliminate the premature degradation of silicon allow for record-breaking battery energy density of up to 350 Wh/kg and lowering EV prices to be competitive with ICEs. Differently sized cells of the same format (shape) with the same chemistry may have different energy densities. Jelly roll cells usually have a higher energy density than coin or prismatic cells of the same Ah, because of a tighter/compresses packing of the cell layers. Among cylindrical cells, those with a larger size have a larger energy density, albeit the exact value strongly depends on the thickness of the electrode layers. The disadvantage of large cells is decrease of the heat transfer from the cell to its surroundings.
=== Balkans and Greece === After the Battle of Leros, New Zealand withdrew its squadron from the Long Range Desert Group, compelling the LRDG to reorganise itself into two squadrons of eight patrols each. A Squadron was composed of Rhodesians and B Squadron comprised British troops and a squadron of signallers; around 80 of the officers and men were from Southern Rhodesia. The group was reassigned from the Middle East Command to the Central Mediterranean Force in early 1944, and deployed to the Gargano peninsula in south-eastern Italy, where a new LRDG headquarters was set up near the seaside town of Rodi. Britain hoped to compel the Germans to commit as many divisions as possible to south-eastern Europe so they could not be used on the more important fronts closer to Germany. In June 1944 the LRDG was assigned to operate on the coast of Yugoslavia, with orders to set up observation posts, report the movements of German ships and undertake minor raids.
These mechanism-based methods use knowledge about the polymerase amplification process to generate estimates of the original sample concentration. An extension of this approach includes an accurate model of the entire PCR reaction profile, which allows for the use of high signal-to-noise data and the ability to validate data quality prior to analysis. According to research of Ruijter et al. MAK2 assumes constant amplification efficiency during the PCR reaction. However, theoretical analysis of polymerase chain reaction, from which MAK2 was derived, has revealed that amplification efficiency is not constant throughout PCR. While MAK2 quantification provides reliable estimates of target DNA concentration in a sample under normal qPCR conditions, MAK2 does not reliably quantify target concentration for qPCR assays with competimeters.
For services to British Business in South-East Asia. John Worsley Knagg, Director, British Council English Language Centre, Singapore. Lam Shiu-kum. For services to medicine in Hong Kong. Gerald John Laving. For services to British business interests, and to the community, in Russia. Ranee Lee Pui-Leung, . For public and community service in Hong Kong. Shelly Lau Lee Lai-kuen, . Director of Home Affairs, Hong Kong. Edmund Kwong Ho Leung. For services to engineering in Hong Kong. Jurek Martin, Washington Bureau Chief, Financial Times. Patrick Joseph McGuinness, lately First Secretary, British Embassy, Abu Dhabi. Evelyn Hugh Norie. For services to British business interests in Hong Kong. Alan Richardson, , Director, Accounting Services, Hong Kong. Rolf Schild. For public and industrial services. Michael John Steere. For services to British engineering in Norway. Ian Robert Strachan, , Director of Social Welfare, Hong Kong. Robert Wallace. For services to British commercial interests overseas. Michael David Williams, Rabbi to the Copernic community in Paris. David Wong Shou-yeh, . For services to business and the community, Hong Kong. The Honourable Samuel Wong Ping-wai, . For public services, Hong Kong. William John Woods. For services to community health care in Brazil. Raymond Wu Wai-yung. For services to psychiatric rehabilitation in Hong Kong. Helen Yu Lai Ching-ping, , Director of Education, Hong Kong.
=== Heart failure === Although loop diuretics help to treat acute symptoms of heart failure, mineralocorticoid receptor antagonist diuretics (such as spironolactone) can be used long-term to reduce mortality and morbidity associated with certain types of chronic heart failure. A randomized controlled trial in 1999 found that spironolactone reduced death from any cause by 30%, as well as cardiac death and heart failure hospitalisations, in patients with HFrEF on standard therapy. A 2011 randomized controlled trial found similar benefits with eplerenone in HFrEF, supporting the use of mineralocorticoid receptor antagonists in HFrEF when added to contemporary heart failure therapy. Current recommendations from the American Heart Association are to use spironolactone in patients with NYHA Class II-IV heart failure who have a left ventricular ejection fraction of less than 35%. Spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction, but it has no effect on mortality and hospitalization. Due to its antiandrogenic properties, spironolactone can cause effects associated with low androgen levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g., for an acute exacerbation of heart failure. A newer medication, eplerenone, has been approved by the US Food and Drug Administration (FDA) for the treatment of heart failure, and lacks the antiandrogenic effects of spironolactone.
Sources: en.wikipedia.org
=== 18 April === A German government website announced that the country had delivered a Patriot missile system to Ukraine. The United States is yet to confirm if the Patriot system it promised to Ukraine has been delivered. The Ukrainian Interior Ministry announced that it had created an online database of Russian and pro-Russian-separatist soldiers killed in Ukraine. Currently, it identified by name 56,827 "Russian representatives" killed in Ukraine, as well as their place and date of death.
Operation LabScam was a United States government investigation in the 1990s by a seven-member taskforce into laboratory billing fraud resulting in $800 million in fines. Fraudulent billing practices included labs billing Medicare and other government healthcare programs for medically unnecessary tests, upcoded tests, tests that were never conducted, and providing kickbacks to physicians. The following labs were implicated: Damon Clinical Laboratories, SmithKline Beecham Clinical Laboratories (SBCL), Corning Life Sciences, Liberty Testing Laboratory.
=== Japan === One fatal poisoning caused by intravenous injection of a "bath salt" product containing acetylfentanyl mixed with 4'-Methoxy-α-pyrrolidinopentiophenone (a substituted cathinone) has been reported in 2016.
Relative to 150 mg/day bicalutamide, levels of (R)-bicalutamide are about 15% higher at a dosage of 200 mg/day and about 50% higher at a dosage of 300 mg/day. In contrast to (R)-bicalutamide, the inactive enantiomer (S)-bicalutamide is much more rapidly absorbed (as well as cleared from circulation). Steady-state concentrations of the drug are reached after 4 to 12 weeks of administration independently of dosage, with an approximate 10- to 20-fold progressive accumulation of circulating levels of (R)-bicalutamide. The relatively long time to reach steady-state is a product of the long elimination half-life of bicalutamide. With single 50 mg and 150 mg doses of bicalutamide, mean peak concentrations (Cmax) of (R)-bicalutamide are 0.77 μg/mL (1.8 μmol/L) (at 31 hours) and 1.4 μg/mL (3.3 μmol/L) (at 39 hours), respectively. At steady-state, mean circulating concentrations (Css) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L), respectively. In another 150 mg/day bicalutamide study, mean circulating concentrations of (R)-bicalutamide were 19.4 μg/mL (45.1 μmol/L) and 28.5 μg/mL (66.3 μmol/L) on days 28 and 84 (weeks 4 and 12) of treatment, respectively. There is wide interindividual variability, up to 15.7-fold, in steady-state (R)-bicalutamide levels with bicalutamide therapy. This is the case for all dosage levels of bicalutamide, and ranges in (R)-bicalutamide levels for different dosages show significant overlap.
Sources: en.wikipedia.org
Everyone always asks if that is Demri Parrott on the Dirt Cover. I think Demri's name might have been mentioned as a possible model once or twice, but it was never a serious consideration. In an interview with the Canadian magazine M.E.A.T. in December 1992, Layne Staley said about the cover:
== External links == Overview of all the structural information available in the PDB for UniProt: P05305 (Endothelin-1) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
where e represents the charge on the electron and the sphere. Haas combined this constraint with the balance-of-forces equation. The attractive force between the electron and the sphere balances the centrifugal force:
== Importance in winemaking == Assimilable nitrogen is an essential nutrient needed by wine yeast in order to fully complete fermentation with a minimum amount of undesirable by-products (such as compounds like hydrogen sulfide that can create off odors) created. Over the course of a fermentation, yeast may use up to a 1000 mg/L of amino acids though often far less than amount is needed. Yeast can store amino acids in intracellular vacuoles and then later either use them directly, incorporating them into proteins, or break them down and use their carbon and nitrogen components separately. In the absence of nitrogen, yeast will begin to shut down and die off. Some strains will begin breaking down sulfur containing amino acids like cysteine and methionine releasing a sulfur atom that can combine with hydrogen to produce hydrogen sulfide (H2S) which can impart rotten egg odors to the wine. However, there is not a direct correlation between YAN levels and hydrogen sulfide production since H2S can be produced by yeast even in the presence of abundant nitrogen but with instead other vital nutrients (such as the vitamin pantothenic acid) lacking. There are even some strains of S. cerevisiae that produce H2S as a response to having too much available nitrogen (particularly too much glutamic acid and alanine). This is why a prophylactic approach of indiscriminately adding nitrogen supplementation to every fermentation may not have the desired results of preventing H2S.
The failure to gain improved rights for uitlanders (notably the dynamite tax) became a pretext for war and justification for a military build-up in Cape Colony. The case for war was developed and espoused as far away as the Australian colonies. Cape Colony Governor Sir Alfred Milner; Rhodes; Chamberlain; and mining syndicate owners such as Beit, Barney Barnato, and Lionel Phillips, favoured annexation of the Boer republics. Confident that the Boers would be quickly defeated, they planned and organised a short war, citing the uitlanders' grievances as the motivation. In contrast, the influence of the war party within the British government was limited. Prime Minister Lord Salisbury despised jingoism. He was uncertain of the abilities of the British Army. Despite his moral and practical reservations, Salisbury led the UK to war to preserve the Empire's prestige and a feeling of obligation to British South Africans. Salisbury detested the Boer treatment of native Africans, referring to the London Convention of 1884, following Britain's defeat in the first war, as an agreement "really in the interest of slavery". Salisbury was not alone in this. Roger Casement, already on the way to becoming an Irish Nationalist, was nevertheless happy to gather intelligence for the British against the Boers because of their cruelty to Africans.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.